Following the March 2026 Tavneos vasculitis drug safety alert from the FDA, we are investigating possibly related deaths and liver injuries legal cases to be filed against the drug company Amgen on behalf of patients using Tavneos who developed serious liver side effects or the families of those patients who died.
Tavneos Vasculitis Drug Safety
The March 2026 Tavneos vasculitis drug safety alert from the FDA came soon after Amgen rejected an FDA request in February 2026 for a Tavneos recall over concerns about drug-induced liver injury (DILI) and vanishing bile duct syndrome (VBDS) liver side effects, as well as reports made to the FDA about death cases involving Tavneos.
Despite these FDA warnings about the DILI and VBDS liver injuries, and even with those deaths linked to Tavneos, there has been no indication from Amgen that there will be a Tavneos recall.
In general terms, Tavneos (avacopan) is a vasculitis drug used together with other medications. In more detail, Tavenous is typically used with glucocorticoids and other standard-of-care medications to treat adults with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis).
A March 31, 2026 Drug Safety Communication, “FDA Identifies Cases of Serious Liver Injury in Patients Taking Tavneos (avacopan) for Severe Active Anti-neutrophil Cytoplasmic Autoantibody (ANCA)-associated Vasculitis“, is the March 2026 Tavneos vasculitis drug safety alert from the FDA that we refer to above.
Deaths and Liver Injuries Legal Cases
The possibly related deaths and liver injuries legal cases we mentioned at the outset would not be filed against the patient’s doctors who prescribed the Tavneos or the doctors who treated their Tavneos liver injuries due to our contention that Amgen has failed to sufficiently warn about the drug-induced liver injury (DILI) and vanishing bile duct syndrome (VBDS) side effects associated with Tavneos.
If you have a possible Tavneos liver injury or death legal compensation case that you want reviewed as a lawsuit filed against Amgen, you can submit a Drug Injury Case Evaluation Form online, send an email to TJL@LambLawOffice.com, or call us at 910-256-2971.
[Read the article in full at Drug Injury Watch]Tavneos
Free Case Evaluation
Strictly Confidential, No Obligation